TY - JOUR
T1 - Characteristics and Outcomes of Patients Consulted by a Multidisciplinary Pulmonary Embolism Response Team
T2 - 5-Year Experience
AU - Pietrasik, Arkadiusz
AU - Gąsecka, Aleksandra
AU - Kurzyna, Paweł
AU - Wrona, Katarzyna
AU - Darocha, Szymon
AU - Banaszkiewicz, Marta
AU - Zieliński, Dariusz
AU - Zajkowska, Dominika
AU - Smyk, Julia Maria
AU - Rymaszewska, Dominika
AU - Jasińska, Karolina
AU - Wasilewski, Marcin
AU - Wolański, Rafał
AU - Procyk, Grzegorz
AU - Szwed, Piotr
AU - Florczyk, Michał
AU - Wróbel, Krzysztof
AU - Grabowski, Marcin
AU - Torbicki, Adam
AU - Kurzyna, Marcin
N1 - Funding Information: Funding: This manuscript was supported by the Centre of Postgraduate Medical Education, project number 501-1-054-25-22. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - (1) Background: Pulmonary embolism (PE) is the third most frequent acute cardiovascular condition worldwide. PE response teams (PERTs) have been created to facilitate treatment implementation in PE patients. Here, we report on the 5-year experience of PERT operating in Warsaw, Poland, with regard to the characteristics and outcomes of the consulted patients. (2) Methods: Patients diagnosed with PE between September 2017 and December 2021 were included in the study. Clinical and treatment data were obtained from medical records. Patient outcomes were assessed in-hospital, at a 1-and 12-month follow-up. (3) Results: There were 235 PERT activations. The risk of early mortality was low in 51 patients (21.8%), intermediate–low in 83 (35.3%), intermediate–high in 80 (34.0%) and high in 21 (8.9%) patients. Anticoagulation alone was the most frequently administered treatment in all patient subgroups (altogether 84.7%). Systemic thrombolysis (47.6%) and interventional therapy (52%) were the prevailing treatment options in high-risk patients. The in-hospital mortality was 6.4%. The adverse events during 1-year follow-up included five deaths, two recurrent VTE and two minor bleeding events. (4) Conclusions: Our initial 5-year experience showed that the activity of the local PERT facilitated patient-tailored decision making and the access to advanced therapies, with subsequent low overall mortality and treatment complication rates, confirming the benefits of PERT implementation.
AB - (1) Background: Pulmonary embolism (PE) is the third most frequent acute cardiovascular condition worldwide. PE response teams (PERTs) have been created to facilitate treatment implementation in PE patients. Here, we report on the 5-year experience of PERT operating in Warsaw, Poland, with regard to the characteristics and outcomes of the consulted patients. (2) Methods: Patients diagnosed with PE between September 2017 and December 2021 were included in the study. Clinical and treatment data were obtained from medical records. Patient outcomes were assessed in-hospital, at a 1-and 12-month follow-up. (3) Results: There were 235 PERT activations. The risk of early mortality was low in 51 patients (21.8%), intermediate–low in 83 (35.3%), intermediate–high in 80 (34.0%) and high in 21 (8.9%) patients. Anticoagulation alone was the most frequently administered treatment in all patient subgroups (altogether 84.7%). Systemic thrombolysis (47.6%) and interventional therapy (52%) were the prevailing treatment options in high-risk patients. The in-hospital mortality was 6.4%. The adverse events during 1-year follow-up included five deaths, two recurrent VTE and two minor bleeding events. (4) Conclusions: Our initial 5-year experience showed that the activity of the local PERT facilitated patient-tailored decision making and the access to advanced therapies, with subsequent low overall mortality and treatment complication rates, confirming the benefits of PERT implementation.
KW - PERT
KW - catheter-based therapies
KW - pulmonary embolism
KW - pulmonary embolism response team
UR - http://www.scopus.com/inward/record.url?scp=85133127565&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/jcm11133812
DO - https://doi.org/10.3390/jcm11133812
M3 - Article
C2 - 35807097
VL - 11
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
SN - 2077-0383
IS - 13
M1 - 3812
ER -